A 78-joints ultrasonographic assessment is associated with clinical assessments and is highly responsive to improvement in a longitudinal study of patients with rheumatoid arthritis starting adalimumab treatment.

To examine associations between ultrasonography (US) assessments (B-mode (BM) and power Doppler (PD)) of a large number of joints and traditional assessments of disease activity, and to examine the sensitivity to change of the US scores and clinical measures in patients with rheumatoid arthritis (RA).
Twenty patients with RA initiating adalimumab treatment were examined at baseline and after 1, 3, 6 and 12 months with US (BM and PD) using an Outcome Measures in Rheumatoid Arthritis Clinical Trial semiquantitative scoring (0-3) of 78 joints as well as assessment of clinical and laboratory variables with calculation of composite indexes.
The US scores were associated with composite scores as well as clinical and laboratory variables (r=0.41-0.84, p<0.05-0.001 at 12-months' follow-up). Compared with clinical assessments, US detected higher numbers of inflamed joints. The US scores decreased after 1 and 3 months (p<0.005) and PD showed the highest percentage improvement. Both BM and PD had high standardised response means throughout the study (-0.83 to -1.27), of similar magnitude to composite indexes, but higher than the clinical and laboratory variables.
The comprehensive US assessments were associated with clinical and laboratory variables of disease activity and were highly sensitive to change during treatment with biological agents.
AuthorsHilde Berner Hammer, Margareth Sveinsson, Anne Katrine Kongtorp, Tore K Kvien
JournalAnnals of the rheumatic diseases (Ann Rheum Dis) Vol. 69 Issue 7 Pg. 1349-51 (Jul 2010) ISSN: 1468-2060 [Electronic] England
PMID20472599 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • Prednisolone
  • Adalimumab
  • Methotrexate
  • Adalimumab
  • Adult
  • Aged
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents (therapeutic use)
  • Arthritis, Rheumatoid (drug therapy, ultrasonography)
  • Drug Therapy, Combination
  • Female
  • Humans
  • Joints (ultrasonography)
  • Longitudinal Studies
  • Male
  • Methotrexate (therapeutic use)
  • Middle Aged
  • Prednisolone (therapeutic use)
  • Severity of Illness Index
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha (antagonists & inhibitors)
  • Ultrasonography, Doppler
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: